TPA-023B manufacturers
- TPA-023B
-
- $1400.00
-
2026-04-21
- CAS:425377-76-0
- Purity:
- Supply Ability: 10g
|
| | TPA-023B Basic information |
| Product Name: | TPA-023B | | Synonyms: | TPA-023B;[1,1'-Biphenyl]-2-carbonitrile, 2',6-difluoro-5'-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-yl]-;BAY-2873384;TPA 023B,TPA023B;2',6-difluoro-5'-(3-(2-hydroxypropan-2-yl)imidazo[1,2-b][1,2,4]triazin-7-yl)-[1,1'-biphenyl]-2-carbonitrile | | CAS: | 425377-76-0 | | MF: | C21H15F2N5O | | MW: | 391.37 | | EINECS: | | | Product Categories: | | | Mol File: | 425377-76-0.mol |  |
| | TPA-023B Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | Light yellow to green yellow |
| | TPA-023B Usage And Synthesis |
| Uses | TPA-023B is a high-affinity and orally active GABAA receptor α2/α3 subtype (Kis of 0.73 nM/2 nM) partial agonist and a α1 subtype (Ki of 1.8 nM) antagonist. TPA-023B has non-sedating anxiolytic-like properties[1]. | | in vivo | TPA-023B gives dose- and time-dependent occupancy of rat brain GABAA receptors as measured using an in vivo [3H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL[1].
TPA-023B is anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet has no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%[1]. | | References | [1] Atack JR, et al. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. J Psychopharmacol. 2011 Mar;25(3):329-44. DOI:10.1177/0269881109354928 |
| | TPA-023B Preparation Products And Raw materials |
|